Silvia Finotto

891 total citations
18 papers, 291 citations indexed

About

Silvia Finotto is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Silvia Finotto has authored 18 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 7 papers in Genetics and 7 papers in Oncology. Recurrent topics in Silvia Finotto's work include Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Silvia Finotto is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Silvia Finotto collaborates with scholars based in Italy and United States. Silvia Finotto's co-authors include Francesco Rodeghiero, Carlo Visco, Rossella Paolini, Gianpietro Semenzato, Giovanni Pizzolo, Renato Zambello, Roberta Zanotti, Francesco Zaja, Emanuele S.G. dʼAmore and Marco Ruggeri and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Oncologist.

In The Last Decade

Silvia Finotto

18 papers receiving 288 citations

Peers

Silvia Finotto

PFM

GENET

ONCOL

HEMAT

IMMUN

Anna Ruskova New Zealand

Jennifer L. Cultrera United States

Emmanuelle Tchernonog France

Mayur Narkhede United States

Aurélie Verney France

Lucille Baseggio France

Eva Berra Italy

Ana Batlle Spain

Claudia Mannu Italy

Anna Ruskova New Zealand

Silvia Finotto

184 ×1.0

PFM

93 ×0.6

GENET

97 ×0.8

ONCOL

53 ×1.2

HEMAT

63 ×1.6

IMMUN

Citations per year, relative to Silvia Finotto Silvia Finotto (= 1×) peers Anna Ruskova

Countries citing papers authored by Silvia Finotto

Since Specialization

Citations

This map shows the geographic impact of Silvia Finotto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Finotto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Finotto more than expected).

Fields of papers citing papers by Silvia Finotto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Finotto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Finotto. The network helps show where Silvia Finotto may publish in the future.

Co-authorship network of co-authors of Silvia Finotto

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Finotto. A scholar is included among the top collaborators of Silvia Finotto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Finotto. Silvia Finotto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Russo, Irene, Dario Marino, Claudia Cozzolino, et al.. (2024). Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series. Cancers. 16(4). 691–691. 4 indexed citations

Marino, Dario, Marco Pizzi, Ronny Schmidt, et al.. (2022). High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. Cancers. 14(2). 338–338. 6 indexed citations

Olivieri, Jacopo, Rossella Paolini, Silvia Finotto, et al.. (2021). Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma. Cancers. 13(23). 6089–6089. 8 indexed citations

Bonometti, Arturo, Emanuela Passoni, Silvia Finotto, & Emilio Berti. (2021). Nail involvement in Langerhans cell histiocytosis and its association with multisystem presentation and lung involvement. Indian Journal of Dermatology Venereology and Leprology. 87(6). 850–854. 1 indexed citations

Maruzzo, Marco, Davide Bimbatti, Silvia Finotto, et al.. (2021). High dose chemotherapy followed by autologous hematopoietic stem cell transplantation for advanced germ cell tumors: State of the art and a single-center experience. Critical Reviews in Oncology/Hematology. 169. 103568–103568. 5 indexed citations

Milan, Elisa, et al.. (2021). Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin. Molecular and Clinical Oncology. 14(6). 121–121. 3 indexed citations

Brunello, Antonella, Antonella Galiano, Silvia Finotto, et al.. (2020). Older cancer patients and COVID‐19 outbreak: Practical considerations and recommendations. Cancer Medicine. 9(24). 9193–9204. 14 indexed citations

Marino, Dario, Silvia Finotto, Umberto Basso, et al.. (2020). To Transplant or Not to Transplant During the SARS-CoV-2 Pandemic? That Is the Question. The Oncologist. 26(2). e336–e337. 1 indexed citations

Rastrelli, Marco, Saveria Tropea, Silvia Finotto, et al.. (2019). Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera. In Vivo. 33(5). 1667–1669. 12 indexed citations

10.

Visco, Carlo, Silvia Finotto, Renato Zambello, et al.. (2013). Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology. 31(11). 1442–1449. 126 indexed citations

11.

Visco, Carlo, Agostino Cortelezzi, Francesca Moretta, et al.. (2013). Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?. Leukemia & lymphoma. 55(6). 1261–1265. 12 indexed citations

12.

Falisi, Erika, Elisabetta Novella, Carlo Visco, et al.. (2013). B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. Hematological Oncology. 32(1). 22–30. 22 indexed citations

13.

Visco, Carlo, Silvia Finotto, Roberto Sartori, et al.. (2013). The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia. American Journal of Hematology. 88(4). 289–293. 14 indexed citations

14.

Visco, Carlo, Francesca Moretta, Erika Falisi, et al.. (2013). Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. American Journal of Hematology. 88(4). 277–282. 10 indexed citations

15.

Olíva, Esther Natalie, Valeria Santini, Gina Zini, et al.. (2012). Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). Blood. 120(21). 923–923. 14 indexed citations

16.

Albiero, Elena, Marco Ruggeri, Sara Fortuna, et al.. (2011). Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica. 97(1). 123–127. 24 indexed citations

17.

Visco, Carlo, Renato Zambello, Rossella Paolini, et al.. (2011). Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen In Patients with Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant. Blood. 118(21). 2677–2677. 9 indexed citations

18.

Ruggeri, Marco, et al.. (2010). Treatment outcome in a cohort of young patients with polycythemia vera. Internal and Emergency Medicine. 5(5). 411–413. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact